

Drug Repurposing Guidebook

Building Block E142

This document defines the content of the FACT SHEET to be created for each identified tool, incentives, initiative or practice (the Building Block) introduced by public bodies or used by developers to expedite drug repurposing in Rare Diseases (RDs).

ITEM	DESCRIPTION
Building Block (BB) Title	EATRIS – European Infrastructure for Translational Medicine
References	www.eatris.eu https://doi.org/10.1038/nrd.2017.72 (European best practices and infrastructure for biomarker validation) Publications citing EATRIS - EATRIS
Description	EATRIS is the European Infrastructure for Translational Medicine. It brings together resources and services for research communities to translate scientific discoveries into benefits for patients. It offers a broad range of research services for both academia and industry across various research fields. In addition, it works with public funding agencies, charities and policy makers with tailored actions to help improve the translational research and innovation ecosystem. EATRIS coordinates the Horizon Europe project REMEDI4ALL that aims to establish an EU platform for Drug Repurposing. EATRIS has currently 127 institutions in 14 EU member states as its members.
Category	Supporting tools
Type of BB	Development resource
Geographical scope	Europe
Availability	It is available for users (researchers, charities, patient organisations, industry) that are in need of translational research capacity or expertise. A Coordination and Support office in Amsterdam serves as central point of contact to process requests and set up (tailor made) collaborations.

ITEM	DESCRIPTION
Scope of use	EATRIS can provide access to specific resources or expertise required to translate research findings to the clinic, ranging from predictive models (in vitro and in vivo), biomarker validation, drug target engagement studies, pharmaceutical development (e.g. reformulation) to clinical/disease expertise patient centric drug repurposing approaches. Non-technical services include innovation management support to RD research projects, regulatory and health technology, mentoring and education & training.
Stakeholders involved	EATRIS is a membership organization with a central office based in Netherlands (hosted by AmsterdamUMC, location VUmc). It has currently 14 EU member states with a total of 127 academic research institutions and medical centers as service providers. Its users range from academic researchers, pharma, biotech to charities and it engages with policy makers
Enablers/ Requirements	The more specific the research requests the better the matching expertise can be identified (e.g. clear drug repurposing hypothesis/rationale, gaps in research plan). If research requests need to be further defined, experts can be involved to do so. Specific drug repurposing expertise will be gathered in expert teams in REMEDI4ALL that can perform a gap analysis of the project. Users need to bring funding. Public-private collaborations can be facilitated.
Output	New research collaborations, regulatory compliant repurposing development plans, services, drug repurposing portfolio (REMDi4ALL platform), engagement with policy makers, education & training programs, international networking,
Best time to apply and time window	EATRIS – continuously. REMDi4ALL is in construction phase 2022-2023 after which it will be open to users to explore collaborative research projects and using the specific drug repurposing expertise gathered in the platform.
Expert tips	Generate a Target Product Profile describing the repurposing drug minimal requirements and opportunities compared to current standard of care. This helps the generation of a clear development plan with the end goal in mind.

ITEM	DESCRIPTION
	<p>Consider the medical need as a driver for the project and identify opportunities where patients can be involved in project design and/or decision making.</p> <p>Identify gaps in the project as detailed and as early as possible.</p> <p>Consult drug development, IP and regulatory experts to generate an understanding of the non-technical challenges of the development path.</p> <p>Also check the BB on https://remedi4all.org/</p>